NAV

Reviparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Reviparin
DrugBank Accession Number
DB09259
Background

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.1 It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.2 It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.3

Type
Small Molecule
Groups
Approved, Investigational
Synonyms
  • Reviparin sodium

Pharmacology

Indication

By the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients.3

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Reviparin is been shown to present significant inhibition of smooth muscle cell migration and proliferation in human cell cultures without affecting endothelial cell growth.1

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Reviparin.
AcebutololThe risk or severity of hyperkalemia can be increased when Acebutolol is combined with Reviparin.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Reviparin.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Reviparin.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Reviparin.
Albutrepenonacog alfaThe therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Reviparin.
AlclofenacThe risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Reviparin.
AldesleukinThe risk or severity of bleeding can be increased when Reviparin is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Reviparin is combined with Alemtuzumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
B01AB08 — Reviparin
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5XQ9UBJ16W
CAS number
9041-08-1
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol. 1996 Nov 15;28(6):1437-43. [Article]
  2. Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S: Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol. 2000 Apr;49(4):337-41. [Article]
  3. FDA orphan list [Link]
KEGG Drug
D03337
PubChem Substance
347910423
RxNav
75960
Wikipedia
Reviparin_sodium
MSDS
Download (52.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentNeoplastic Disease / Venous Thromboembolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionParenteral1750 IU/0.25mL
Injection, solutionParenteral5726 IE
Injection, solutionSubcutaneous
Injection, solutionParenteral10307 IU/0.6mL
Injection, solution
SolutionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility50 mg/ml'MSDS'
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at October 26, 2015 16:53 / Updated at August 13, 2020 07:01